Why did Medline lower its full-year 2026 adjusted EBITDA guidance despite reporting 12% sales growth in Q2 2026?

What happened to the guidance

Medline trimmed its full-year 2026 adjusted EBITDA target from $3.5 billion-$3.6 billion down to $3.3 billion-$3.4 billion [1][8][23]. The cut came in the same report that showed second-quarter net sales up about 12% year over year to roughly $7.7 billion [4][7][21].

Why the profit outlook was cut anyway

The main explanation is that costs grew faster than sales could offset them. Medline said the lower outlook primarily reflected four things [1][2]:

• Higher-than-expected inflation from the Middle East conflict, worth about $70 million of impact and including higher fuel and product costs that Medline absorbed rather than passing on to customers [24][31].
• More operational investment to support customer demand, including adding labor three to six months before the related revenue arrives. About half of the extra cost is expected to be permanent [25][29][34].
• Quality remediation work, including delays in bringing back products like recalled CHG wipes, which is expected to keep weighing on earnings into 2027 [26].
• Softness in the retail channel, which management described as Medline-specific: tied to one customer and a sales execution problem rather than a broad market slowdown [16][27][33].

There were also fire-related pressures. The Tracy distribution center fire created $336 million in losses before insurance recoveries, and Medline expected another $50 million-$100 million of additional fire costs in the second half, with some of those costs remaining in the base [6][28]. Management broke down the overall reduction as about 25% from external factors, including the Middle East conflict and Tracy fire, and about 75% from internal factors like operational investment, quality remediation, and retail softness [15][30].

Wait — wasn't Q2 profit actually up?

Reported Q2 adjusted EBITDA did rise about 13% to $1.1 billion, but that figure was flattered by a one-time $243 million net benefit from IEEPA tariff refunds [10][36][50]. Without that benefit, underlying adjusted EBITDA was $817 million [11][32]. The full-year guidance intentionally excluded IEEPA tariff refund benefits, so the reported Q2 profit strength did not carry into the revised outlook [3][14][69].

Tariffs still mattered in another way too: Medline described a 2026 tariff headwind of about $350 million under the new 10% rate, down from the original $490 million estimate but still a drag [35]. Higher operating expenses and tariff-related cost of goods sold also contributed to the profit pressure [5][70].

So the short version

Demand was not the problem. In fact, Medline raised its full-year organic sales growth outlook to 9%-10%, reflecting strong customer demand [18][56]. The issue was that the money coming in from higher sales was being eaten by cost increases, one-time fire and remediation expenses, and investments made ahead of growth [60][61]. One segment showed the pattern plainly: Supply Chain Solutions sales grew 16.3%, but its adjusted EBITDA rose only 1.5% and its margin contracted [72]. Investors still reacted negatively to the reduced profit outlook despite the strong sales report [58].